Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. (NASDAQ: BVS) delivers innovative orthobiologic solutions that advance musculoskeletal healing through clinically proven therapies. This news hub provides investors and healthcare professionals with essential updates on the company’s progress in pain treatments, surgical technologies, and restorative care innovations.
Access real-time announcements including earnings reports, product launches, and strategic partnerships. Our curated collection features regulatory milestones, research developments, and acquisition updates that demonstrate Bioventus’ leadership in active healing technologies.
Discover how the company’s dual focus on internal R&D and targeted acquisitions strengthens its position across 90+ countries. Stay informed about evidence-based solutions addressing sports medicine, trauma care, and complex surgical needs through verified press releases and analyst-reviewed updates.
Bookmark this page for streamlined access to Bioventus’ latest advancements in orthobiologics. Check regularly for insights into how their global network and ethical practices shape the future of musculoskeletal recovery.
Bioventus Inc. (Nasdaq: BVS), a global leader in active healing innovations, has announced its plans to release second quarter fiscal year 2024 financial results on August 6, 2024, before the market opens. The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update.
Interested parties can participate in the conference call by dialing 1-833-636-0497 and referring to the Bioventus Inc. Conference Call. Additionally, a live webcast of the call and accompanying materials will be available on the company's Investor Relations website. The webcast will be archived and accessible for replay until August 5, 2025.
Apyx Medical announced the retirement of Andrew Makrides as Chairman of the Board, who served the company since 1982, and the appointment of Stavros Vizirgianakis as the new Chairman. Makrides contributed to the company's growth over the years, while Vizirgianakis brings extensive medical device industry experience to the role.
Bioventus Inc. (Nasdaq: BVS) reported strong first-quarter financial results with a revenue increase of 8.7% and organic growth of 15.3%. The company raised its full-year 2024 financial guidance, reflecting enhanced revenue growth and strategic execution. Gross margin expanded significantly, and adjusted EBITDA from continuing operations increased by 33.5%. Bioventus achieved key milestones, including revenue growth in Pain Treatments and Surgical Solutions, liquidity enhancement, and EU MDR Certification for Exogen Bone Stimulation System. The company now expects net sales of $535 million to $550 million, adjusted EBITDA of $94 million to $99 million, and non-GAAP EPS of $0.25 to $0.33 for 2024.
Bioventus Inc. (Nasdaq: BVS) will release its financial results for the first quarter of fiscal year 2024 on May 7, 2024. The management will conduct a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update. Participants can join the call by dialing 1-833-636-0497 or accessing the live webcast on the company's website. The webcast will be available for replay until May 6, 2025.
